Monopar Therapeutics Inc.
MNPR
$59.27
-$1.72-2.82%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 47.28% | -0.07% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 50.38% | 26.55% | |||
| Operating Income | -50.38% | -26.55% | |||
| Income Before Tax | -51.29% | -40.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -51.29% | -40.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -51.29% | -40.11% | |||
| EBIT | -50.38% | -26.55% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -26.30% | -37.62% | |||
| Normalized Basic EPS | -26.29% | -37.65% | |||
| EPS Diluted | -26.30% | -37.62% | |||
| Normalized Diluted EPS | -26.29% | -37.65% | |||
| Average Basic Shares Outstanding | 19.79% | 1.80% | |||
| Average Diluted Shares Outstanding | 19.79% | 1.80% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||